These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29293272)

  • 21. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
    Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
    J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
    McAlpine J; Leon-Castillo A; Bosse T
    J Pathol; 2018 Apr; 244(5):538-549. PubMed ID: 29344951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
    Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
    Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic implications of germline genetic findings in cancer.
    Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM
    Nat Rev Clin Oncol; 2019 Jun; 16(6):386-396. PubMed ID: 30783251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
    Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
    Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective.
    Cooper LA; Demicco EG; Saltz JH; Powell RT; Rao A; Lazar AJ
    J Pathol; 2018 Apr; 244(5):512-524. PubMed ID: 29288495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.
    Schachtschneider KM; Gaba RC
    J Vasc Interv Radiol; 2018 Aug; 29(8):1117-1121. PubMed ID: 30055782
    [No Abstract]   [Full Text] [Related]  

  • 31. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
    Horlings HM; Shah SP; Huntsman DG
    JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
    [No Abstract]   [Full Text] [Related]  

  • 32. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
    Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
    JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic sequencing in cancer.
    Tuna M; Amos CI
    Cancer Lett; 2013 Nov; 340(2):161-70. PubMed ID: 23178448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
    Rasnic R; Brandes N; Zuk O; Linial M
    BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine.
    Grellety T; Lucchesi C; Hostein I; Auzanneau C; Khalifa E; Soubeyran I; Italiano A
    Eur J Cancer; 2017 Oct; 84():250-256. PubMed ID: 28841542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A method to reduce ancestry related germline false positives in tumor only somatic variant calling.
    Halperin RF; Carpten JD; Manojlovic Z; Aldrich J; Keats J; Byron S; Liang WS; Russell M; Enriquez D; Claasen A; Cherni I; Awuah B; Oppong J; Wicha MS; Newman LA; Jaigge E; Kim S; Craig DW
    BMC Med Genomics; 2017 Oct; 10(1):61. PubMed ID: 29052513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clear cell carcinomas of the ovary and kidney: clarity through genomics.
    Ji JX; Wang YK; Cochrane DR; Huntsman DG
    J Pathol; 2018 Apr; 244(5):550-564. PubMed ID: 29344971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.